Extended Data Fig. 9: Additional validation of the META-16 gene signature.
a, Quantitative reverse transcriptase PCR (qRT-PCR) of META-16 in the CUIMC cohort of bone metastases (n = 5) compared with high-Gleason grade primary prostate tumors (n = 10). Indicated p-values were estimated using a two-tailed Mann-Whitney test compared to the average of all primary tumors. In box plots, boxes show the 25th–75th percentile, center-lines show the median, and whiskers show the minimum–maximum values. b, c, Heatmaps showing expression levels of META-16 genes determined by qRT-PCR following MYC silencing in human and mouse prostate cancer cells. b, qRT-PCR using RNA obtained from subcutaneous PC3-Luc-GFP tumors expressing shRNA against MYC (shMYC#1) or control shRNA (shControl). c, qRT-PCR using RNA obtained from NPKEYFP bone cells grown in vitro and infected with the indicated shRNAs. Scaled values represent ratios of expression compared to shControl for each gene. In b, c, p-values were estimated using z-score sums of all genes using two-tailed, unpaired t-test (b) or one-way ANOVA with Dunnett’s multiple comparisons against shControl (c).
